文献速递妇科

靶向TROP2的抗体偶联药物Dato-DXd对原代宫颈癌细胞系及异种移植瘤的临床前有效活性

Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts.
PubMed 文献 · Gynecol Oncol · 2025-09-03

本研究在表达TROP2的原代宫颈癌细胞系及小鼠异种移植瘤中评估了靶向TROP2的抗体偶联药物Dato-DXd的临床前药理作用。67%(4/6)的原代宫颈癌细胞系高表达TROP2,Dato-DXd对TROP2表达细胞系(CVX4和CVX8)诱导显著肿瘤细胞死亡,对TROP2不表达细胞系(ADX2)无杀伤作用,并观察到旁观者杀伤效应及ADCC活性。体内实验中Dato-DXd有效抑制TROP2阳性异种移植瘤生长,结论认为有必要在晚期/复发宫颈癌患者中开展临床评价。

要点

  • 67%(4/6)的原代宫颈癌细胞系高表达TROP2。
  • Dato-DXd对TROP2表达细胞系CVX4和CVX8诱导肿瘤细胞死亡,对TROP2不表达细胞系ADX2无杀伤作用。
  • TROP2阳性CVX4与TROP2阴性ADX2共培养时,Dato-DXd对ADX2细胞显示显著旁观者杀伤活性。

核心结论

  • Dato-DXd对表达TROP2的原代宫颈癌细胞系及异种移植瘤显示出显著的临床前活性。
  • 作者认为有必要在晚期/复发宫颈癌患者中开展Dato-DXd的临床评价。

研究设计与样本

  • 临床前药理学研究,采用原代宫颈癌细胞系及表达TROP2的宫颈癌小鼠模型。
  • 通过流式细胞术鉴定TROP2表达水平不同的原代宫颈癌细胞系。
  • 在TROP2表达和不表达细胞系中于系列稀释浓度下评估Dato-DXd诱导的肿瘤细胞死亡。
  • 采用CFSE孵育细胞系,将TROP2表达肿瘤细胞与不表达肿瘤细胞混合后评估Dato-DXd的旁观者杀伤能力。
  • 采用磷酸化H2AX评估Dato-DXd诱导的凋亡,采用标准4小时51Cr释放试验评估抗体依赖性细胞毒性(ADCC)。

主要发现

  • 67%(4/6)的原代宫颈癌细胞系高表达TROP2。
  • Dato-DXd在TROP2表达细胞系(CVX4和CVX8)中高效诱导肿瘤细胞死亡,而对TROP2不表达细胞系(ADX2)未诱导杀伤。
  • TROP2阳性肿瘤细胞(CVX4)与TROP2阴性肿瘤细胞(ADX2)在Dato-DXd存在下共培养时,对ADX2细胞观察到显著旁观者活性。
  • Dato-DXd暴露增加磷酸化H2AX(凋亡标志物),并在TROP2表达模型中诱导显著水平的ADCC。
  • 体内实验中,Dato-DXd有效抑制肿瘤生长,荷TROP2阳性异种移植瘤小鼠第50天时中位总生存期未达到。

临床怎么用

  • 原文结论指出,有必要在晚期/复发宫颈癌患者中开展Dato-DXd的临床评价。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cervical cancer is one of the most prevalent and deadly cancers worldwide. Here we demonstrate the preclinical pharmacology of Dato-DXd, a TROP2-targeting antibody-drug conjugate (ADC), against primary cervical cancer cell lines and xenografts. METHODS: Primary cervical cancer cell lines with differential TROP2 expression were identified by flow cytometry. Tumor cell death was evaluated at serial dilutions of Dato-DXd in TROP2-expressing and non-expressing cell lines. CSFE-incubated lines were evaluated for the ability of Dato-DXd to induce bystander killing after admixing TROP2-expressing tumor cells with non-expressing tumor cells. Dato-DXd-induced apoptosis was evaluated using phosphorylated H2AX. Antibody-directed cellular cytotoxicity (ADCC) was evaluated using a standard 4-h 51Cr assay. Finally, the in vivo anti-tumor activity of Dato-DXd was assessed in TROP2-expressing cervical cancer mouse models. RESULTS: 67 % (4/6) of primary cervical cancer cell lines showed high expression of TROP2. Dato-DXd was highly effective in inducing tumor cell death in TROP2-expressing cell lines (CVX4 and CVX8) while no killing was induced against TROP2 non-expressing cell lines (ADX2). When TROP2+ tumor cells (CVX4) were co-cultured with TROP2 negative tumor cells (ADX2) in the presence of Dato-DXd, significant bystander activity was noted against ADX2 cells. Dato-DXd exposure increased phosphorylated H2AX, a marker of apoptosis, and induced significant levels of ADCC in TROP2-expressing models. In vivo, Dato-DXd was effective in tumor growth suppression and the median overall survival was unreached by day 50 in mice harboring TROP2+ xenografts. CONCLUSION: Dato-DXd demonstrated remarkable preclinical activity against TROP2-expressing primary cervical cancer cell lines and xenografts. Clinical evaluation of Dato-DXd is warranted in advanced/recurrent cervical cancer patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ettorre VM, Demirkiran C, Bellone S, et al. Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts. Gynecol Oncol. 2025. PMID: 40907200. doi:10.1016/j.ygyno.2025.08.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。